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Contraluminal organic anion and cation transport in the
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Contraluminal organic anion and cation transport in the proximal renal
tubule: V. Interaction with suifamoyl- and phenoxy diuretics, and with
13-lactam antibiotics. In order to study the interaction of sulfamoyl- and
phenoxy diuretics as well as of /3-lactam antibiotics with the contralu-
minal anion and cation transport systems the inhibitory potency of
these substances against the influx of 3H-para-aminohippurate, '4C-
succinate, 35S-sulfate and 3H-N'-methylnicotinamide into cortical tubu-
lar cells have been determined. 1.) 2-, 3- and 4-sulfamoylbenzoate
inhibit contraluminal PAH influx. N-dipropyl substitution to yield
probenecid or ring-substitution to yield furosemide and piretanide
augment the inhibitory potency. However, hydrochlorothiazide and
acetazolamide exert only a moderate inhibitory potency. Succinate
transport was inhibited by furosemide only. Sulfate transport was
inhibited by furosemide and 3-sulfamoyl-4-phenoxybenzoate as well as
by probenecid, piretanide, hydrochlorothiazide and acetazolamide. 2.)
Phenoxyacetate, -propionate, and -butyrate exert increasing inhibition
against PAH transport. The weed-killers 2,4-dichloro-, and 2,4,5-
trichlorophenoxyacetate (2,4 D and 2,4,5 T) had a similar inhibitory
potency, while ethacrynic acid showed a lower and the uricosuric
tienilic acid a higher inhibitory potency. None of the compounds of this
group interact with contraluminal succinate transport, and only the
multiring-substituted compounds 2,4 D, 2,4,5 T, ethacrynic and tienilic
acid interact slightly with the sulfate transporter. 3.) The monocarboxy-
lic penicillins benzylpenicillin and phenoxymethylpenicillin as well as
the dicarboxylic ticarcillin interact with the contraluminal PAH trans-
port. The aminopenicillin ampicillin had a lower, and apalcillin a higher
inhibitory potency than monocarboxylic penicillin. Benzylpeniciliin
showed small inhibition against succinate transport and ticarcillin
against sulfate transport, 4.) The monocarboxylic cephalosporine, 6315
S Shionogi, and the aminocephalosporines, cephalexin and cefadroxil,
showed an app. KIPAH as the comparable penicillins. The zwitterions
cephaloridine and cefpirome did not interact with the PAH transporter,
but with the organic cation (NMN) transporter. Amongst the amino-
thiazol-containing compounds cefotaxime, ceftriaxone, and cefodizime,
increasing interaction with the PAH transporter was seen dependent of
a second ionizable anionic group. Compounds with two ionizable
anionic groups (cefsulodin, ceftnaxone, cefodizime) exert also a small
inhibitory potency against sulfate transport. None of the cephalosporins
interacted with the dicarboxylate transporter, The interaction pattern of
the tested compounds is in accordance with the specificity requirements
for the contraluminal transporters depending on electrical charge and
hydrophobicity.
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An important function of the kidney is the secretion of drugs
and xenobiotics and of their metabolites. The magnitude of
renal excretion has an important impact on the drug's half-life
and, thereby, on systemic drug levels. An impaired excretion
may cause drug or xenobiotic accumulation in the body and
give rise to toxic effects. An impairment of excretion can occur
through lesions of tubule segments responsible for drug secre-
tion or through competition between two drugs or xenobiotics
for a common, rate-limiting secretory transport system in
tubule cells. To better understand and even to avoid unwanted
drug interference, it is mandatory to elucidate the molecular
mechanisms which are responsible for drug excretion in the
kidney. The goal of the present study is, therefore, to determine
the transport systems that take up sulfamoyl- and phenoxy
diuretics as well as /3-lactam antibiotics from the blood into the
proximal tubule cell.
Drugs and xenobiotics are secreted in proximal tubules via
transport systems for organic anions and cations. In previous
experiments we have established the specificity requirements of
the transporters for p-aminohippurate, dicarboxylate and sul-
fate located in the contraluminal membrane of proximal renal
tubular cells [reviewed in 1, 2]. The PAH transport system
interacts with hydrophobic molecules carrying one or two ionic
negative charges or at least two partially negative charges. The
dicarboxylate carrier accepts molecules with two negative
charges at a proper distance of 5 to 9 A. Finally, the sulfate
transporter interacts with molecules with neighboring electro-
negative charge accumulation. Many drugs and xenobiotics
fulfill these requirements and are transported by renal proximal
tubules [reviewed in 3—5]. Since some drugs are zwitterions and
might be transported by anion as well as cation transport
systems, we established, in addition to the anion transport
tests, an organic cation transport test with [3H]-N'-methylnico-
tinamide as substrate. The results of our studies show that the
interaction of probenecid, of the diuretics furosemide, pireta-
nide, hydrochlorothiazide, acetazolamide, ethacrynic and tie-
linic acid, and of the f3-lactam antibiotics of the penicillin and
cephalosporin type interact with the anion and cation transport
systems in a predictable fashion.
Methods
The experiments were performed in male Wistar rats
(Winkelmann, Kirchborchen, FRG) of 200 to 250 g body
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weight, fed an Altromin standard diet and tap water. The
animals were anaesthetized by injecting mactin (Byk-Gulden,
Konstanz, FRG), 120 to 150 mg/kg body weight, intraperitone-
ally and placed on a heated operating table with a thermostat
control set at 37°C. An incision was made in the left flank and
the kidney separated from the surrounding fascia. The capsule
was stripped off. The kidney was immobilized in a plastic cup
on cotton wool and covered with paraffin oil heated to 37°C.
The renal artery and vein were isolated from the ureter so that
they could be clamped. The renal artery and vein were clamped
for each measurement of the disappearance rate of the radiola-
belied substances. The proximal convoluted tubules then col-
lapsed because the luminal fluid was reabsorbed, while glomer-
ular filtration ceased. Immediately thereafter, a thick superficial
capillary was impaled by an oil-filled sampling pipette (tip
diameter about 6 m) for sample collection. At a distance of 100
to 140 sm from this glass capillary another blood vessel was
punctured with a filling pipette (tip diameter about 8 pm).
Through the filling pipette a rapid injection of an isotonic
solution containing different concentrations of radiolabelled
substances and inulin as extracellular space marker was made.
After 1 to 4 seconds, as checked by an acoustic signal, the test
solution was withdrawn into the sampling pipette.
The experiments with '4C-succinate [6], 35S-sulfate [7], 3H-
para-aminohippurate [8] and 3H-N '-methylnicotinamide [9]
were performed as described in the respective references. The
3H-'4C and 35S-radioactivity of the test substances and that of
the reference substance (3H- or '4C-inulin) were measured in a
Betamatik I Kontron scintillation counter with Picofluor 15
(Packard, Frankfurt/Main, FRG) as scintillation fluid. Since the
control values varied during the two-year time period in which
the experiments were performed, the experimental data were
appropriately corrected.
The standard solution injected into the capillaries, for the
35S-sulfate and 3H-para-aminohippurate experiments, con-
tained in mmol/liter: 150 Na, 4 K, 154 gluconate. In the '4C-
succinate and 3H-N'-methylnicotinamide experiments the stan-
dard solution contained: 146 Nat, 4 K, 1.5 Ca2, 1 Mg2, 130
C1, 25 HC03. All added substances replaced an equivalent
amount of gluconate or chloride so that the osmolality remained
constant. The solutions were gassed with pure °2 in the sulfate
and para-aminohippurate experiments, but with 95% N2, 5%
CO2 in the dicarboxylate and N '-methylnicotinamide experi-
ments. The pH was set to 7.4. Further specifications are given
in the legends to the figures.
The apparent K1-values (app. K1) were evaluated as described
in [6]. The apparent K. values were used as operational values,
since competitive inhibition is assumed, but not proven explic-
itly. All values are given as means SEM. The applied method
has its limits at K1504 > 25 mmollliter, > 10 mmol/liter,
KINMN and K.PAH > 5 mmol/liter. K1 values closely below
and above these limits therefore show a rather large SEM. The P
values were calculated from an unpaired t-test. The specific
activities of the isotopic tracers used were as follows: 35SO42
1400 Ci/mmol; 3H-PAH 6.8 Ci/mmol; '4C-inulin 15 mCi/g and
3H-inuiin 164 mCiIg; these isotopes were obtained from Du Pont
(NEN, Dreieich, FRG). '4C-succinate with a specific activity of
Ill mCi/mmol was obtained from Amersham Buchier (Frank-
furt/Main, FRG). 3H-N' methylnicotinamide (3 Ci/mmol) was
obtained from ICN-Biochemicals (Eschwege, FRG). The
source of the inhibitors used is indicated in Tables 1 and 2,
where (a) = Aldrich-Chemie, Steinheim, FRG; (bw) =
Beecham-Wulfing, Neuss, FRG; (c) = Ciba-Geigy, Wehr, FRG;(0 = Fluka GmbH, Neu-Ulm, FRG; (g) = Grunenthai, Stol-
berg, FRG; (h) = Hoechst AG, Frankfurt/M, FRG; (hi) =
Hoechst AG, Dr. H.-J. Lang, Frankfurt/M, FRG; (hr) =
Hoffmann-La Roche, Grenzach-Wyhlen, FRG; (in) = ICN,
Plainview, New York, USA; (I) = Lederle, MUnchen, FRG;
(msd) = Merck, Sharp Dohme, MUnchen, FRG; (s) Sigma =
Deisenhofen, FRG; (st) = Stadapharm, Bad Vilbel, FRG; (sh)
= Shionogi Co., Dr. Masuhisa Nakamura, Osaka, Japan; (th) =
Thomae, Biberach, FRG.
Results
Sulfamoyl compounds and diuretics
Benzenesulfonamide with only partial negative charges ex-
erts only a small inhibitory potency against contraluminal PAH
transport (app. K1 PAR 1.95 mmoi/liter; Fig. 1, Table 1) [2].
However, if the benzene ring has in addition a carboxylic
group, the app. K1 drops about 10-fold: 2-suifamoyi-benzoate
app. K-pAR 0.27 mmol/liter, 3-sulfamoylbenzoate 0.18 mmol/
liter, and 4-sulfamoylbenzoate 0.3 mmoL/liter. N-dipropyl sub-
stitution of the latter compound which yields probenecid aug-
ments the affinity toward the PAH transporter further, that is,
again by a factor of about 10 (app. K'PAH 0.03 mmol/liter). If
3-sulfamoyl-benzoate is further ring-substituted with a chloro-
or phenoxy group, the app. KIPAR remains in this range
(3-sulfamoyl-4-chlorobenzoate, app. KIPAH 0.05 mmoLlliter;
3-sulfamoyl-4-phenoxybenzoate, app. KIPAH 0.05 mmoi/liter).
Also a fourth substitute, a furylmethylamino group which yields
the diuretic furosemide or a pyrrolidine group, as in the case of
the diuretic piretanide, does not change the affinity (furosemide
app. KIPAH 0.04 mmol/liter, piretanide app. KIPAH 0.07 mmoL1
liter). In contrast, the diuretic hydrochiorothiazide or the car-
bonic anhydrase inhibitor acetazolamide have a much lower
affinity (hydrochlorothiazide app. KI,PAH 0.72, acetazolamide
1.3 mmol/liter). As the interaction with the contraiuminai dicar-
boxylate transport concerns, only the doubly para-substituted
furosemide (app. 5.1 mmol/liter) exerts a small inhibitory
potency.
Interaction with the contralurninal sulfate transporter was
seen with probenecid (app. K50 7.3 mmol/liter), 3-sulfamoyl-
phenoxybenzoate (app. K1 ,S042 — 0.78 mmol/liter), furosemide
(app. K15042— 0.87 mmol/liter), piretanide (app. K1so42— 2.9
mmol/liter), hydrochlorothiazide (app. K15042— 4.4 mmol/liter),
and acetazolamide (app. K15O42— 6.4 mmol/liter).
Phenoxy compounds (weed killers and diuretics)
Increasing the phenoxy side chain from acetate through
propionate to butyrate the app. K1 against the contraluminal
PAH transporter drops from 0.4 to 0.27 to 0.04 mmol/liter (Fig.
2, Table 1). The di- and trichloro-ring-substituted phenoxyace-
tates, 2,4-dichlorophenoxyacetate and 2,4,5-trichlorophenoxy-
acetate, have a high affinity (app. K1 PAR 0.03 and 0.05 mmol/
liter). Interestingly, the affinity of the diuretic ethacrynic acid
(app. K1 PAR 0.12 mmol/liter) and that of the uricostatic diuretic
tienilic acid (app. K1 PAR 0.01 mmol/liter) are different from
each other by a factor 10. No interaction of the phenoxy
compounds with the contraluminal succinate transporter was
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observed. A small interaction with the contraluminal sulfate
transporter was, however, seen with all 2- and 3-fold substi-
tuted phenoxyacetates: 2,4 dichlorophenoxyacetate, app.
K1s042— 10.4; 2,4,5-trichlorophenoxyacetate, 4.2; ethacrynic
acid, 4.7, and tienilic acid, 2.7 mmol/liter.
Penicillins
The one carboxylic group bearing penicillins benzylpenicillin
(penicillin G) and phenoxymethylpenicillin (penicillin V) exert a
moderate inhibitory potency against the contraluminal PAH-
transporter (app. KIPAH 0.81 and 0.7 mmollliter, respectively;
Fig. 3, Table 2). Benzylpenicillin with an additional amino
group to yield ampicillin has a much lower inhibitory potency
(app. KIPAR 2.5 mmol/liter). Interestingly, the apposition of a
NH-CO-linked hydroxy-naphthyridin group to ampicillin to
yield apalcillin gives a very high inhibitory potency (app.
K1PAH 0.02 mmoL/liter). The dicarboxylic penicillin ticarcillin
with an apparent KIPAH of 0.84 mmol/liter has a potency like
penicillin 0 and V. Among the five penicillins tested, benzyi-
penicillin showed a small inhibitory potency against dicarboxy-
late transport (app. K1 15.8 mmollliter) and tricarcillin against
sulfate transport (app. K1 8.2 mmol/liter), but none against
N1-methylnicotinamide transport.
Cephalosporins
The aminocephalosporin compound cephalexin (app. KIPAH
2.3 mmoi/iiter), which has the same structural formula as
ampicillin except that the five-membered thiazolidin ring of the
penicillins is extended to the six-membered dihydrothiazin ring
of the cephalosporins, has also the same inhibitory potency
against contraluminal PAH transport (Fig. 4, Table 2). The
incorporation of an additional OH-group to yield cefadroxil
(app. KIPAH 3.0 mmol/liter) does not change the affinity. The
monocarboxylic cephalosporin compound 6315 S Shionogi
(app. KIPAH of 0.94 mmol/liter) exerted the same affinity as the
monocarboxylic penicillins. Monocarboxylic cephalosporins
with an aminothiazol side group, such as cefotaxime, has a
K,PAH of 3.1 mmol/liter, those with an ionizable enol group,
that is, ceftriaxone, an app. KIPAH of 1.5 mmot/liter, and those
with a second carboxylic group, that is, cefodizime, an app.
KIPAH of 0.22 mmol/liter. Monocarboxylic cephalosporins with
a positively charged pyridin group do not interact with the PAH
transporter. However, when the net charge becomes negative
by addition of a second anionic sulfonate group (cefsulodin app.
K1 PAR 1.9 mmol/iiter) a small interaction with the PAH trans-
porter is seen. Among the cephalosporins tested, only the
Table 1. Effect of benzenesulfamoyl and phenoxyacetate analogs on contraluminal influx of 35S-sulfate (4s), 3H-para-aminohippurate (2s), and
'4C-succinate (is) into cortical renal tubular cells
Para-amino-hippurate Succinate Sulfate
K. K1 K1
Substances added m c(%±sE) (mM±sE) m c(%±sE) (mM±sE) ma c(%+sE) (mM±SE)
Control 46.6 0.9 65.3 1.1 47.0 0.9
Benzenesuifonamide (t) 10 34.5 2.0 1.9 1.0 10 72.9 1.4 >10 5 43.8 1.8 >25
2-Sulfamoylbenzoate (h) 10 10.7 2.2 0.27 0.09 10 68.5 3.8 >10 5 43.0 3.4 >25
(saccharine)
3-Sulfamoylbenzoate (hi) 10 7.4 1.8 0.18 0.05 10 73.0 3.5 >10 5 43.7 2.0 >25
4-Sulfamoylbenzoate (a) 10 11.2 2.2 0.3 0.09 10 65.4 2.0 >10 5 48.0 1.0 >25
Probenecid (msd) 1 11.2 2.5 0.03 0.005 10 63.5 2.5 >10 50
5
18.2 2.6
39.4 2.2
7.9 2.2
7.3 10.4
3-Sutfamoyl-4-chloro- 1 17.9 2.6 0.05 0.01 10 61.2 3.7 10 5 42.4 3.9 >25
benzoate (hi)
Furosemide (h) 10
1
6.0 3.5
14.2 3.1
0.14 0.02
0.04 0.01
10 48.9 3.2 5.1 8.9 5 19.0 3.4 0.87 0.3
3-Sulfamoyl-4-phenoxy- 1 17.3 2.9 0.05 0.01 10 62.0 3.1 >10 5 18.0 4.0 0.78 0.23
benzoate (hi)
Piretanide (h) 10
1
0.5 1.9
20.6 2.7
0.01 0.001
0.07 0.02
10 67.3 2.1 >10 5 32.5 2.9 2.9 1.9
Hydrochiorothiazide (s) 10 21.5 1.9 0.72 0.19 10 58.9 2.1 >10 5 36.3 2.9 4.4 4.3
Acetazolamide (1) 10 29.3 1.7 1.3 0.47 10 60.3 3.7 >10 5 38.7 1.4 6.4 7.7
Phenoxyacetate (f) 10
1
20.2 1.4
41.6 3.8
0.65 0.17
0.4 0.51
10 70.6 3.1 >10 5 48.6 2.0 >25
Phenoxypropionate (in) 10 10.7 1.7 0.27 0.05 10 69.6 3.4 >10 5 50.3 2.4 >25
4-Phenoxybutyrate (t) 10
0.5
2.6 1.1
20.4 2.8
0.05 0.01
0.03 0.01
10 66.0 2.8 >10 5 48.3 3.1 >25
2,4-Dichlorophenoxy- 1 10.6 3.0 0.03 0.01 10 68.8 2.8 >10 5 41.0 2.7 10.4 21.3
acetate (a)
2,4,5-Trichlorophenoxy- 1 17.2 2.9 0.05 0.01 10 63.6 4.3 >10 5 35.9 2.0 4.2 3.7
acetate (a)
Ethacrynic acid (msd) 1 27.9 2.0 0.12 0.04 10 67.5 2.6 >10 5 36.7 3.1 4.7 4.8
Tienilic acid (h) 1 5.7 2.3 0.01 0.002 10 60.8 3.7 >10 5 31.9 2.2 2.7 1.6
The starting concentration in the capillary perfusate was for 3H-para-aminohippurate 0.1, 0.15, and for 35S-sulfate 0.01
mmol/liter. The first column indicates the compounds tested and their source (Methods), the 2nd, 5th and 8th column their concentration. The 3rd,
6th and 9th column indicate the percent decrease in contraluminal concentration relative to inulin during the respective contact time sri. The 4th,
7th and 10th column give the apparent K1±SE values in m calculated by a computer program according to refs. 6, 10 and 11.
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Table 2. Effect of penicillins and cephalosporins on contraluminal influx of '4C-succinate (Is), 3H-para-aminohippurate (2s), 35S-sulfate (4s)
and 3H-N'-methylnicotinamide (4s) into cortical renal tubular cells
N '-methyl-nicotinamide
Para-amino-hippurate Succinate Sulfate C1
K, K, K, K,
Substances added m c(%±sE) (mM±sE) msi c(%±sE) (mM±sE) msi c(%±sE) (mM±sE) mri c(%±sE) (mM±sE)
Control 46.6 0.9 65.3 1.1 47.0 0.9
Benzylpenicillin (s) 10 23.1 2.7 0.81 0.24 10 56.7 2.4 15.8 6.9 5 50.1 3.3 >25 5 35.1 3.2 >5
Phenoxymethyl- 10 21.1 2.6 0.7 0.18 10 61.3 4.8 >10 5 46.1 1.7 >25 5 42.0 2.4 >5
penicillin (s)
Ampicillin (st) 10 37.4 2.1 2.5 1.55 10 60.8 3.6 >10 5 43.7 2.4 >25 5 34.0 3.2 >5
Apalcillin (th) 0.1 32.6 3.8 0.02 0.01 10 63.8 2.1 >10 5 44.9 2.6 >25 5 36.0 1.4 >5
Ticarcjllin (bw) 10 23.5 2.1 0.84 0.24 10 65.7 1.6 >10 5 40.0 2.3 8.2 13.2 5 39.2 1.6 >5
Cephaloridine (s) 25
10
41.9 2.9
45.6 3.2
>5
>5
10 62.6 4.2 >10 5 49.8 4.0 >25 5 23.2 2.5 2.1 0.8
Cefpirome 10 50.0 3.2 >5 10 67.0 1.7 >10 5 47.8 3.2 >25 5 14.6 2.6 0.9 0.3
(HR 810) (h)
Cefsulodin (g) 10 34.4 2.2 1.9 1.0 10 64.8 1.8 >10 5 39.3 2.6 7.2 10.0 5 34.8 2.7 >5
Cefotaxime (h) 25
10
2
28.7 2.2
47.5 1.9
46.2 3.2
3.1 1.1
>5
2.2 5.5
10 63.3 4.1 >10 5 46.5 1.9 >25 5 31.8 3.5 >5
Ceftriaxone (hr) 10 29.7 3.2 1.5 0.7 10 60.7 2.4 >10 5 41.7 2.4 12.7 3.0 5 40.2 2.8 >5
Cefodizime 10 8.8 1.6 0.22 0.06 10 62.6 2.3 >10 5 36.7 1.6 4.7 4.4 5 40.8 1.6 >5
(HR 221) (h)
6315 5 Shionogi 10 25.1 2.0 0.94 0.28 10 67.4 2.6 >10 5 48.1 1.3 >25 5 33.0 3.9 >5
(sh)
Cephalexin (h) 10 36.2 2.0 2.3 1.25 10 68.8 2.6 >10 5 49.9 3.0 >25 5 39.7 2.5 >5
Cefadroxil (c) 10 39.0 2.6 3.0 2.2 10 66.0 2.1 >10 5 43.7 1.6 >25 5 33.8 1.9 >5
The starting concentration in the capillary perfusate was for 3H-para-aminohippurate 0.1 mmol/liter, for '4C-succinate 0.15, for 35S-sulfate 0.01,
and for 3H-N'-methylnicotinamide 0.1 mmol/Iiter. The first column indicates the compounds tested and their source (Methods), the 2nd, 5th, 8th
and 11th column their concentration. The 3rd, 6th, 9th and 12th column indicate the percent decrease in contraluminal concentration relative to
inulin during the respective contact time SE. The 4th, 7th, 10th and 13th column give the apparent K1±SE values in m calculated by a computer
program according to refs. 6, 10 and 72.
zwitterionic cephaloridine (app. KINMN 3.7 rmol/liter) and
cefpirome (app. KNMN 1.3 mmol/liter) interact with the con-
traluminal organic cation transport. Interestingly, all three
compounds which had two ionizable anionic groups interacted
with the sulfate transport system (cefsulodin app. K15042— 7.2
mmollliter; ceftriaxone app. K1so42— 12.7 mmol/liter; and cefo-
dizime app. Kso42— 4.7 mmol/liter).
Discussion
A semiquantitative structure interaction relationship [11, 12]
can now be established for contraluminal organic anion trans-
port processes, because enough basic information is available.
This study attempts to relate the chemical structure of drugs
and xenobiotics to their interaction with the organic anion and
cation transport systems at the contraluminal cell side of the
proximal renal tubule. So far, three different anion transport
systems have been identified [1, 111: for hydrophobic anions
(PAH), for dicarboxylates and for sulfate. The PAH transport
system interacts with hydrophobic molecules carrying one or
two negative ionic charges or two or more negative partial
charges. In the case of benzoates and phenolates log KIPAH is
proportional to the log PKa values [2]. The dicarboxylate
transporter requires two electronegative ionic charges at 5 to 9
A distance [11], where one of the two charges may be a partial
charge. The sulfate transporter interacts with molecules which
have neighboring electronegative charge accumulation. In con-
trast to the anion transport systems, there no evidence exists
for the presence of more than one contraluminal organic cation
transport system.
Sulfonamides
Benzenesulfonamide exerts an inhibitory potency against
contraluminal PAH transport with a KIPAH of 1.9 mmol/liter,
which is in the same range as that of the readily ionized
benzenecarboxylate (benzoate, app. KpAH 1.5 mmol/liter) or
benzenesulfonate (app. KIPAH 1.9 mmollliter) [2]. Thus, it
behaves like a hydrophobic anion, although the PKa value of the
SO2 NH2 group ranges between 9.4 and 10.3; that is, it behaves
like a very weak acid and thus is similar to that of phenols [2].
As expected from their structural formulae hydrochlorothiazide
(app. KIPAH 0.72 mmol/liter) and acetazolamide (app. KpAfl
1.3 mmol/liter) exert similar inhibitory potencies. In concert
with a C00-group, however, the sulfamoyl group behaves
like an electronegative partially-charged group such as Cl,
HCO, NO2, or a second negative ionic charge, which both
augment the affinity toward the PAH transporter considerably
[2]. Furthermore, if an additional hydrophobic moiety (N-
dipropyl) is introduced into the 4-sulfamoylbenzoate molecule
to yield probenecid or a hydrophobic chloro-, phenoxy- or
pyrryl group attached to the ring of the 3-sulfamoylbenzoate to
yield the diuretics SD 14108 (that is, 3-sulfamoyl-4-chloro-
benzoate), furosemide and piretanide, a high affinity toward the
PAH transporter was seen (app. KIPAH 0.05 mmol/liter).
Furthermore, these groups are electron attracting, which is
electronegative. Thus, the substances mentioned qualitatively
follow the rules found for interaction with the PAH transporter
[1, 2].
It is more difficult to tell why furosemide interacts with the
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Paraaminohippurate Succinate Sulfate
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Fig. 1. Effect of sulfamoylbenzoate and analogues on contraluminal influx of 3H-para-aminohippurate, '4C-succinate and 35S-sulfate into renal
cortical cells. The respective values of contact time, starting concentration, control decrease of contraluminal test-concentration during the
indicated contact time, and concentration of the added competitors were: in the 3H-para-aminohippurate series: 2 seconds, 0.1 mmol/liter, 0.047
mmol/liter, 10 mmol/liter, solid bar, 1 mmol/liter dotted bar; in the 14C-succinate series: 1 second, 0.15 mmollliter, 0.098 mmollliter, 10 mmol/liter;
in the 35S-sulfate series: 4 seconds, 0.01 mmol/liter, 0.0047 mmol/Iiter, 5 mmol/liter. Each bar represents the mean SCM of 7 to 18 samples from
2 to 4 animals.
dicarboxylate transporter and other sulfamoyl compounds do proper distance. In contrast, most of the tested substances
not, although they fulfill the requirement for interaction, that is, interact with the sulfate transporter although some of them
they have one anionic plus one electronegative group at a (probenecid and acetazolamide) do not fulfill the requirement of
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the negative group accumulation. This leads us to suppose that
the SO2NH2 group has preference toward the sulfate trans-
porter as compared with other electronegative groups.
The present study shows that almost all pharmacologically
important benzenesulfonamides interact with more than one
contraluminal anion transport system:
1.) The carbonic anhydrase inhibitor acetazolamide interacts
with the PAH and sulfate transporter.
2.) The diuretics piretanide, furosemide and hydrochlorothia-
zide interact also with the PAH and sulfate transporter. In
addition furosemide also interacts with the dicarboxylate
transporter.
3.) The "organic anion transport inhibitor" probenecid inter-
acts with very high affinity with the PAH transporter,
while its interaction with the sulfate transporter is rather
weak.
Probenecid and congeners as well as PAH exert mutual
inhibition of their renal clearances [14—17], of accumulation in
kidney cortical slices [18—201, and of uptake into basolateral
membrane vesicles [21, 221. Since probenecid accumulation in
renal slices was inhibited by PAH to a relatively smaller extent
than expected, Sheik et al [5, 20] discussed the possibility that
probenecid might be transported by a "subsystem for organic
anion transport". Although the interaction of probenecid with
the sulfate transport system which we observed is rather weak
(Fig. I, Table 1), such a possibility indeed exists. Inhibition by
probenecid and/or PAH was also seen for renal transport of
acetazolamide [23, 24], hydrochlorothiazide [13, 25, 26], and
indirectly via inhibition of diuresis by furosemide [27—30] and
piretanide [31]. Since some authors felt that acetazolamide as
well as hydrochlorothiazide excretion by the kidney is rather
low, Maren [32] as well as Peters and Roch-Ramel [33] dis-
cussed that besides secretion and non-ionic back diffusion, an
"element of active reabsorption" might be involved in overall
renal handling of these substances. Our finding that acetazol-
amide as well as hydrochlorothiazide interact with two contra-
luminal anion transporters support such a suggestion, since the
probability of countertransport is given if two or more systems
are involved. In fact, however, that interaction with all three
contraluminal anion transporters does not necessarily diminish
renal clearance was seen with furosemide, where with protein-
free renal perfusion its clearance was as high as that of
para-aminohippurate [34]. Net transport of a substance across
the proximal tubular cell layer depends on concentration,
affinity and driving force of that substance for the different
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transport system at the contraluminal and luminal cell side with
which the substance interacts. Even if we knew the complete
transport characteristic of a substance with all transporters
involved, the mutual interaction with other substrates makes a
prediction of net transport rates almost impossible.
Phenoxybenzoate compounds (weed killers and diuretics)
The affinity of these compounds against the contraluminal
PAH transporter increases with their hydrophobicity from
phenoxyacetate (app. KIPAR 0.4 mmol/liter) to phenoxybuty-
rate (app. KIPAH 0.05 mmollliter). Similarly, the introduction of
chloro-groups into phenoxyacetate as well as the introduction
of the methylenebutyryl or thienylcarbonyl group increases
their hydrophobicity. All these compounds exerted a high
inhibitory potency against the PAH transporter. Since the PKa
values of the phenoxy compounds, which we tested, did not
deviate very much from each other, the main determinant for
interaction seems to be the hydrophobicity. On the other hand,
steric effects as we have seen previously with the interaction of
cis and trans-cinnamate toward the PAH transporter [Fig. 9 in
ref. 2] cannot be excluded, especially with ethacrynic acid, the
KIPAH of which is relatively high, and which has a double bond
in the side chain.
From our specificity pattern against the other two contralu-
minal anion transport systems it is not surprising that none of
the compounds interacted with the succinate transporter, but
that the multi-ring-substituted compounds interacted to a small
degree with the sulfate transporter. In whole organ or kidney
slice experiments the application of probenecid and/or para-
aminohippurate inhibits the transport of phenoxyacetate [35], 2,
4-dichioro- or 2,4,5-trichlorophenoxyacetate [36—38], etha-
crynic acid [39], and tienilic acid [40—42]. Similar to the sulfa-
moyl diuretics, probenecid diminishes the diuretic effect of
ethacrynic acid [43]. Thus, a common transport mechanism for
PAH, probenecid and phenoxycarboxylates is evident. Unfor-
tunately, the high serum protein binding of polysubstituted
phenoxy compounds and their non-ionic back diffusion [42, 43]
precludes a quantitative comparison of clearance data with our
transport data. Elimination from the blood is low [36, 44] and
partially due to biotransformation and excretion by the liver
[43, 45]. Furthermore, it is premature to speculate about
transport of these compounds through the contraluminal sulfate
transporter and luminal anion transporters during overall tubu-
lar secretion.
Penicillins
Already in the early forties it was seen that penicillin is
excreted by the kidney via the organic anion transport system
[reviewed in 5, 46]. Probenecid was even developed to retard
renal excretion of penicillin [47, 48] as was the case with PAH
[49]. In man the clearance of unbound benzylpenicillin is as high
as that of PAH [48, 50, 51]. The clearance of unbound ampicil-
un, however, is only half the value [52]. Our data (Fig. 3, Table
2) show that the five penicillins tested interact with the contra-
luminal PAH transport system, although the affinity of the
monocarboxylates benzylpenicillin and phenoxymethylpenicil-
un as well as of the dicarboxylic ticarcillin is rather moderate.
The reason for this might be the moderate hydrophobicity of
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Fig. 3. Effect of penici/lins on contraluminal influx of 3H-para-aminohippurate, '4C-succinate, 35S-sulfate and 3H-N'-methylnicotinamide into
renal cortical cells. Experimental conditions are in Fig. I legend. For 3H-N'-methylnicotinamide contact time was 4 seconds; starting NMN
concentration 0.1 mmollliter, control decrease of NMN during 4 seconds contact time 0.036 mmol/liter and concentration of the added competitors
5 mmol/liter. Cor. means that the inhibition, seen with other concentrations than 10 mmol/liter (Table 2), is recalculated for 10 mmollliter.
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these compounds (log P0 1.7, 2.0 [12] and 1.2, respectively).
If, however, the hydrophobicity is very high as with apalcillin
(log P0 3.4),! the inhibitory potency toward the PAH transport
system increases considerably. In addition, this compound
shows high protein binding and excretion by the liver. In the
case of ampicillin (log P0 1.5) the electropositivity of the
NH2-group with an PKa of 7.24 seems to be responsible for the
The log P of undissociated ticarcillin and apalcillin were calcu-
lated by Dr. G. Gorlik, Hoechst AG, Frankfurt, using the program
CLOGP 3.4. The ig P0 of undissociated apalcillin was also determined
experimentally by us.
reduction of inhibitory potency. At the pH of our perfu sate only
half of the added compound is in the form of an anion, the other
hall is zwitter-ionic. Thus, the degree of interaction of the
tested penicillins with the PAH transport system could be
explained satisfactorily by the rules established recently [1, 2].
Cephalosporins
Among the J3-lactam antibiotics a much larger variety of
cephalosporins is available compared with penicillins [53, 54].
Some of the cephalosporins are zwitterions [55] which are
transported by anion as well as cation transport systems across
luminal and contraluminal cell membranes [56—59]. Further-
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more, at the luminal cell side, transport of /3-lactam antibiotics
share the system for H-dipeptide cotransport [60—62]. Thus,
the overall behavior of those substances in transtubular trans-
port become rather complicated and almost unpredictable. One
step toward better understanding is to select examples from
each group of cephalosporins and to test their interaction with
contraluminal anion and cation transport. As can be judged
from Figure 4 and Table 2, a clear correlation of structure and
interaction could be seen: 1.) The zwitter-ionic cephaloridine
and cefpirome interact with the organic cation (NMN) trans-
port system only, but not with the three anion transport
systems. 2.) If a zwitterion has a surplus negative charge (such
as, cefsulodin) it interacts with the PAH and sulfate transporter,
but not with the NMN transporter. 3.) "Normal" monocar-
boxylic cephalosporins (that is, 6315 S Shionogi) and amino-
cephalosporins (cephalexin and cefadroxil) behave like the
respective penicillin compounds; they show a moderate to low
affinity toward the PAH system. Very interesting is the behav-
ior of the aminothiazol compounds cefotaxime, ceftriaxone and
cefodizime. Cefotaxime showed only a small interaction, but
with an additional electronegative group, that is, enolic OH in
ceftriaxone and a second carboxylic group in cefodizime, the
interaction with the PAH system increased. Furthermore, an
interaction with the sulfate system was seen. Unfortunately, no
correlation of our data gained in the rat with the renal plasma-
free clearances could be established when measured in humans
[63]. Thus, cephaloridine with a plasma-free clearance of 160
mllmin, cefsulodin with 115, ceftriaxone with 150 mI/mm use,
as our data show, different contraluminal transport systems: the
PAH plus sulfate transporter or the NMN transporter. Thus,
for these substances no or an only small net secretion seems to
exist, which was also shown in stop flow studies with cephalo-
ridine [591. On the other hand, cefotaxime and cephalexin with
a plasma-free clearance of 240 mI/mm in humans show only
a small interaction with the PAH transport system in the rat.
Cephaloridine is an example for a nephrotoxic drug [64—69].
Its nephrotoxicity seems to correlate with the intracellular
concentration of this drug [58, 70]. Probenecid, sulfonamides
and other organic anions were shown to inhibit cephaloridine
nephrotoxicity in mice and chickens [59], while organic cations
were shown to augment it in rabbits [71, 72]. If these substances
act via modification of the intracellular cephaloridine concen-
tration, probenecid should act by inhibiting contraluminal up-
take as shown for rabbit [58] and dog [56] or by augmenting
luminal efflux. In contrast, the organic cations should act by
augmenting contraluminal uptake or inhibiting luminal efflux,
the latter being suggested for rabbit [72]. Since cephaloridine
exerted inhibition only against the contraluminal organic base
transport system in our experiments in rats, but none against
the contraluminal anion transport systems, we would argue that
there exist considerable species differences. Conclusions about
nephrotoxicity, transport and interaction of different transport
systems are only allowed if the pertinent data are from the same
species. For future studies it seems to be possible to obtain
more information about the complicated interactions: 1.) by
performing similar interaction studies as in this study with the
luminal transport systems, 2.) by application of '9F-NMR-
measurements of clearance and intracellular concentrations of
fluorinated cephalosporins and interaction studies with test
substrates for the different transport systems, 3.) by application
of '9F-NMR-measurements with fluorinated test substrates [64]
and by studying the interaction with the different cephalospo-
rins. Using this approach the evaluation of competitive inhibi-
tion and/or trans-stimulative acceleration of cephalosporins and
other substrates at either cell side seems to be feasible [73].
Conclusions
The excretion of a substance by the kidney comprises a)
glomerular filtration, b) additional proximal tubular net secre-
tion or reabsorption, and c) possibly additional non-ionic back
diffusion in the distal nephron. Besides protein binding which
determines the filtered amount, proximal tubular net secretion
or reabsorption are the main variables of drug or xenobiotic
excretion. By evaluating correlations of molecular structure
and interaction with the contraluminal anion transport systems
we made the first step in a new approach to understand net
secretory or reabsorptive behavior of a variety of diuretics and
antibiotics on the cellular level. With some substances our data
already explain their net transport behavior, at least in a
qualitative way, and with others the non-consistence of our
contraluminal interaction data with clearance data indicate that
after binding to the anion transporters further transport steps
are rate limiting in transtubular transport, that is, translocation
through the respective transporter(s) or transport through the
anion transporter(s) at the opposite cell side. In addition,
parallel and counter transport through other anion transporters
at either cell side must be considered. For practical purposes it
will be satisfactory to define the main route of transtubular
transport for a given drug or xenobiotic, and to find out whether
existing side routes can be neglected.
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